- Advertisement -
- Advertisement -
- Advertisement -

Find a job

Subscribe for free

All things Pharma

SENISCA awarded Innovate UK grant to develop oligonucleotide therapeutics

SENISCA, a biotechnology company developing RNA based therapeutics to reverse cellular senescence and target the diseases of ageing, today announces that it has been awarded a £571,350 grant from Innovate UK, the UK’s innovation agency, towards the development of oligonucleotide therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF).

Built on 15 years of research, SENISCA’s proprietary technology is harnessing RNA biology to rejuvenate aged ‘senescent’ cells. Senescent cells behave differently to young, healthy cells in a number of ways, such as ceasing growth or secreting pro-inflammatory chemicals. Senescent cells, with a pro-inflammatory profile and disrupted function, are emerging as causal factors for multiple age-related diseases, including IPF.

SENISCA is developing novel advanced biologic therapies utilising oligonucleotides, short strands of DNA or RNA, engineered by SENISCA to reverse senescence in IPF-specific tissues. Early, compelling preclinical data generated by SENISCA have shown that these proprietary senotherapeutic oligonucleotides have beneficial impact on IPF biomarkers.

The Innovate UK grant will enable SENISCA to rapidly progress preclinical work towards IND filing.

Professor Lorna Harries, SENISCA’s Chief Scientific Officer said: “Our technology has real disruptive potential for the treatment of the diseases of ageing. This is an exciting research project that will build on the previous work carried out by SENISCA that led to the identification of a new and druggable set of target genes which enable significant senescence reversal effect in primary human cell models.”

Kirsty Semple, SENISCA’s CEO said: “Our ambition is to be the world-leader in the development and use of senotherapeutic oligonucleotides to treat complex disease. This project has the potential to lead to an innovative avenue of investigation for novel IPF therapeutics, capable, for the first time, to attenuate the IPF disease mechanism and potentially to reverse the condition rather than mitigating symptoms only. We are grateful to Innovate UK for their support and look forward to reporting our progress to address this unmet medical need.”

- Advertisement -
Emma Cooper
Emma Cooper
Emma is Content Manager at Pf Media.

MORE FROM AUTHOR

- Advertisement -

LATEST POSTS

Subscribe

Sign up to receive our digital newsletter, for all the essential headlines, Jobs of the Week and thought-provoking features.

Claim my free subscription